Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Allogene Therapeutics, Inc.
(NASDAQ:ALLO)
$11.4
$-0.28
-2.40%
Allogene Therapeutics, Inc. Chart
ALLO Stock Price Today
Allogene Therapeutics, Inc. (ALLO) stock declined over -2.40% intraday to trade at $11.40 a share on NASDAQ. The stock opened with a gain of 0.09% at $11.462 and touched an intraday high of $11.625, falling -2.40% against the last close of $11.68. The stock went to a low of $11.02 during the session.
Stock Snapshot
$11.68
Prev. Close
1.63 Billion
Market Cap
$11.02
Day Low
$11.462
Open
141.36 Million
Number of Shares
$11.625
Day High
-
P/E ratio
-2.20
EPS (TTM)
3.20
Cash Flow per Share
25.16
Free Float in %
6.81
Book Value
2,298,071
Volume
Allogene Therapeutics, Inc. Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2022-06-30 | $11.462 | $11.625 | $11.02 | $11.4 | 2,264,709 |
| 2022-06-29 | $11.39 | $11.83 | $11.01 | $11.68 | 1,099,800 |
| 2022-06-28 | $11.69 | $11.91 | $11.22 | $11.48 | 1,947,700 |
| 2022-06-27 | $12.22 | $12.5 | $11.6 | $11.7 | 1,151,500 |
| 2022-06-24 | $12.19 | $12.45 | $11.5 | $12.28 | 6,204,800 |
| 2022-06-23 | $12.04 | $12.25 | $11.63 | $12.19 | 2,104,800 |
| 2022-06-22 | $11.22 | $12.22 | $11.06 | $11.96 | 2,227,300 |
| 2022-06-21 | $10.99 | $11.98 | $10.99 | $11.37 | 3,882,700 |
| 2022-06-17 | $9.52 | $11.02 | $9.52 | $10.96 | 8,896,400 |
| 2022-06-16 | $9.25 | $9.55 | $8.93 | $9.42 | 2,710,700 |
Contact Details
Company Information
Employees-
Beta0.43
Sales or Revenue38.49 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
About Company
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Frequently Asked Questions
What is the current Allogene Therapeutics, Inc. (ALLO) stock price?
Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $11.4 as of the last check on Thursday, June 30. During the trading session, ALLO stock reached the peak price of $11.625 while $11.02 was the lowest point it dropped to.
ALLO's industry and sector of operation?
The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Health Care sector. Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
Who are the executives of ALLO?
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Co-Founder & Exec. Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, CEO & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Dr. Eric Thomas Schmidt Ph.D.
Chief Financial Officer
What is the ALLO stock price today?
ALLO stock traded closed the last session at $11.4, which is $-0.28 or -2.40% lower than its previous close of $11.68. ALLO's current trading price is 77.43% lower than its 52-week high of $27.86 where as its distance from 52-week low of 6.43% is -59.08%.
How many employees does ALLO have?
Number of ALLO employees currently stands at -. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.
Link for ALLO official website?
Official Webiste of $ALLO is: https://www.allogene.com
How do I contact ALLO?
ALLO could be contacted at ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States, or at phone #650 457 2700 and can also be accessed through its website.
How many shares of ALLO are traded daily?
ALLO stock volume for the day was 2,298,071 shares while in the previous session number of ALLO shares traded was 2,264,709 . The average number of ALLO shares traded daily for last 3 months was 2.1 Million.
How much did ALLO change today?
The percentage change in ALLO stock occurred in the recent session was -2.40% while the dollar amount for the price change in ALLO stock was $-0.28.
What price range ALLO stock been trading in?
In the recent session, the day high for ALLO stock was $11.625 while the low for ALLO stock touched on the day was $11.02.
What is the market cap of ALLO currently?
The market value of ALLO currently stands at 1.63 Billion with its latest stock price at $11.4 and 141.36 Million of its shares outstanding.